CXMT (688825 CH) H1 2026 (CNY): Revenue 150.3bln (prev. 15.4bln Y/Y), Adj. Net Income 78.8bln (prev. -2.4bln Y/Y)
Newsquawk Staff ·
CXMT (688825 CH) H1 2026 (CNY): Revenue 150.3bln (prev. 15.4bln Y/Y), Adj. Net Income 78.8bln (prev. -2.4bln Y/Y)
What it means
CXMT is China's leading domestic DRAM producer, and the print shows revenue up roughly tenfold year on year with a swing from loss to substantial adjusted profit, a trajectory consistent with a memory maker moving from capacity build-out into volume shipment during an upcycle in DRAM pricing. In past memory cycles, Chinese entrants' results have tracked the commodity price of DRAM rather than idiosyncratic execution, so the operative question is how much of the swing is price versus shipped bit growth, and whether margins hold as legacy-node capacity continues to be added. Earnings of this scale from a Chinese memory maker historically feed into the global supply debate: rapid domestic share gains have on previous occasions pressured pricing at the trailing-edge nodes where incumbents in Korea and Taiwan are most exposed, while leaving leading-edge economics comparatively insulated. The attached tags reference a European insurer and appear to be a tagging error unrelated to the subject. Worth watching is any disclosure on capital expenditure and node migration, since that determines whether the supply overhang narrative intensifies, and the read-across to listed memory peers' pricing commentary. The figures as carried are unusually large relative to the prior year and merit confirmation against the primary filing before being treated as clean.
- Newsquawk Daily Asia-Pac Opening News - 23rd October 2026
- L'Oreal (OR FP) CEO says China market slowed a tiny bit in Q3 but maintained growth rate, favoured by dynamic premium segment
- Kering (KER FP) says traffic remains the main constraint; fashion and leather goods retail sales fell 4% comp., a sequential slowdown reflecting a more challenging environment, less support from Gucci and lower summer traffic, especially in mainland China
- L'Oreal (OR FP) Q3 2026 (EUR): Sales 11.56bln (exp. 11.23bln), Adj. LFL revenue +7.7% (exp. +5.43%); 2026 outlook: sees another year of growth in sales and profit
- Newsquawk Daily US Earnings Estimates - 23rd October 2026: AXP
Related headlines
- China is seeking R&D and supply chain cooperation with Airbus (AIR FP)16 hours ago
- Newsquawk Daily European Opening News - 23rd October 20261 hour ago
- US President Trump signs EO on housing costs, aiming to cut mortgage insurance premiums11 hours ago
- PRE-MARKET JAPANESE AND SOUTH KOREAN STOCKS NEWS: Tech stocks in focus after the sell off in the sector stateside, while SK Hynix cancels plan to list Solidigm unit on the Nasdaq7 hours ago
- PRE-MARKET AUSTRALIAN STOCKS NEWS: Whitehaven Coal (WHC AT) Q1 managed run-of-mine production rose 3% Q/Q to 11.0mln tons, equity sales of produced coal fell 5% Q/Q to 6.0mln tons8 hours ago
- [MARKET ANALYSIS] Asia-Pac stocks are mostly lower following the tech rout and flight-to quality stateside3 hours ago
- Additional European Equity News - 23rd October 20261 hour ago
- US President Trump posts "Senator Roger Marshall of Kansas has done an incredible job in representing his Great State! Because of him....Bombardier is investing 270 MILLION DOLLARS, creating THOUSANDS of American Jobs in Kansas, Texas, and Indiana"3 hours ago
- US President Trump will deliver remarks in Florida on Friday, Georgia on Saturday and Michigan on Sunday, according to The Whiye House8 hours ago
- US President Trump on Iran, says may do it a little bit further10 hours ago
- US President Trump, on Ukraine’s Starlink (SPCX) access, says it’s a very interesting situation; won’t comment on whether he spoke to Elon Musk; bottom line is Musk put it back10 hours ago
- US TREASURY WRAP: T-NOTE FUTURES (Z6) SETTLE 1 POINT AND 9+ TICKS HIGHER AT 106-1311 hours ago
- US President Trump invokes Section 232 on wind turbine imports11 hours ago
- Merck & Co (MRK) and Moderna (MRNA) say safety profile of Intismeran plus Keytruda was generally consistent with previously reported studies of combination; significantly reduced the risk of recurrence or death by 42% compared to Keytruda alone12 hours ago
- US President Trump called Musk and asked him to lift Ukraine Starlink (SPCX) restrictions, WSJ reports13 hours ago